Individual treatment effects in randomized trials with binary outcomes.
From MaRDI portal
Recommendations
- Assessing treatment effect heterogeneity in clinical trials with blocked binary outcomes
- Estimating treatment effect heterogeneity for binary outcomes via Dirichlet multinomial constraints
- Unit–Treatment Interaction and Its Practical Consequences
- Individual treatment heterogeneity in a three period two treatment cross-over design
- Estimating the distribution of heterogeneous treatment effects from treatment responses and from a predictive biomarker in a parallel-group RCT: a structural model approach
Cites work
Cited in
(10)- Sharp bounds on the variance in randomized experiments
- Identification of subpopulations with distinct treatment benefit rate using the Bayesian tree
- Treatment benefit and treatment harm rate to characterize heterogeneity in treatment effect
- Individual treatment heterogeneity in a three period two treatment cross-over design
- Estimating the distribution of heterogeneous treatment effects from treatment responses and from a predictive biomarker in a parallel-group RCT: a structural model approach
- Unit–Treatment Interaction and Its Practical Consequences
- Assessing treatment effect heterogeneity in clinical trials with blocked binary outcomes
- Estimating treatment effect heterogeneity for binary outcomes via Dirichlet multinomial constraints
- Design, identification, and sensitivity analysis for patient preference trials
- A maximum entropy approach for the evaluation of surrogate endpoints based on causal inference
This page was built for publication: Individual treatment effects in randomized trials with binary outcomes.
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q1427505)